By Digifin Pty Ltd · About this coverage
Key Points
- Five-year agreement with HonorHealth with a minimum contracted value of US$0.5 million
- HonorHealth is the fifth U.S. commercial customer and first outside foundation and SAPPHIRE sites
- Additional fee-per-scan revenue possible from Plaque and, after FDA clearance, Flow modules
- Deployment across nine acute-care hospitals serving approximately five million people
About Artrya (ASX:AYA)
Artrya Limited is an ASX-listed medical technology company founded in Perth in 2018. It builds software that reads coronary computed tomography angiography images and reports on coronary artery disease, including the extent of arterial plaque. Its buyers are hospital and health systems, and its commercial market is the United States.
Artrya (ASX:AYA) announced a five-year commercial agreement with Arizona health system HonorHealth, its fifth U.S. commercial customer and the first secured outside its foundation customers and SAPPHIRE study participants.
The agreement has a minimum contracted value of US$0.5 million, which relates to Salix Coronary Anatomy and generates recurring SaaS subscription revenue. Additional fee-per-scan revenue may come from Salix Coronary Plaque and, following FDA clearance, Salix Coronary Flow, and these usage-based amounts are not included in the minimum. Salix is to be deployed across HonorHealth's CCTA network of nine acute-care hospitals across Phoenix and Scottsdale, supported by HonorHealth Heart Care's 40 cardiac specialist offices. HonorHealth serves a population of approximately five million people. Artrya describes HonorHealth as its second largest customer and says the deal builds on the recent Huntsville commercial agreement. Over the longer term, the two parties intend to explore the development of a cardiovascular imaging Centre of Excellence in Arizona.
The release provides no estimates of CCTA scan numbers, so usage-based revenue beyond the minimum is not quantified. Salix Coronary Flow revenue depends on FDA clearance, and the Centre of Excellence is an intention to explore rather than a commitment.
Source: Artrya Limited (ASX:AYA), 13 November 2026. Summary content supplied by Digifin Pty Ltd.
News summary only, not financial advice. It does not consider your objectives, financial situation or needs.